U
DRTX

UBS’s DURATA THERAPEUTICS INC COM STK (DE) DRTX Stock Holding History

UBS’s Portfolio DRTX Stock Details DRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$969K Buy
76,400
+1,000
+1% +$14.9K ﹤0.01% 3625
2014
Q2 		$1.28M Buy
+75,400
New +$1.12M ﹤0.01% 3316

Other funds holding DRTX

AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CPV
Canaan Partners VII Westport, Connecticut $32.3M AUM 154.97% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return

UBS's DRTX Position: Q3 2014 in Review

UBS increased its DURATA THERAPEUTICS INC COM STK (DE) (DRTX) stake by 57% in Q3 2014, buying an estimated $257K and bringing the position to 47,351 shares worth $601K. The position accounts for ﹤0.01% of the portfolio, ranked #4078.

UBS first reported a position in DRTX in Q3 2013 and has held it in 5 quarters since. 70 funds tracked by Wall St. Rank hold DRTX as of Q3 2014.

  • UBS held 47,351 shares of DURATA THERAPEUTICS INC COM STK (DE) worth $601K as of Q3 2014.
  • UBS bought 17,185 DURATA THERAPEUTICS INC COM STK (DE) shares in Q3 2014, an estimated $257K.
  • DURATA THERAPEUTICS INC COM STK (DE) made up ﹤0.01% of UBS's portfolio in Q3 2014, its #4078 holding.
  • UBS first reported a position in DURATA THERAPEUTICS INC COM STK (DE) in Q3 2013 and has held it in 5 quarters since.
  • 70 funds tracked by Wall St. Rank held DURATA THERAPEUTICS INC COM STK (DE) as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.